Elimination of HIV in South Africa through Expanded Access to Antiretroviral Therapy: A Model Comparison Study

PLoS Medicine

Volumn 10, Issue 10, 2013, Pages

  Hontelez, Jan A C ^a,b,c   Lurie, Mark N ^d   Bärnighausen, Till ^c,e   Bakker, Roel ^a   Baltussen, Rob ^b   Tanser, Frank ^c   Hallett, Timothy B ^f   Newell, Marie Louise ^c   de Vlas, Sake J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF KWAZULU NATAL   (South Africa)

^d BROWN UNIVERSITY   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE DURATION; DISEASE TRANSMISSION; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MATHEMATICAL MODEL; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PREVALENCE; RISK; SENSITIVITY ANALYSIS; SEXUAL BEHAVIOR; VIRAL CLEARANCE;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MODELS, THEORETICAL; SOUTH AFRICA;

EID: 84886632425     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001534     Document Type: Article

References (87)

1. Joint United Nations Programme on HIV/AIDS (2012) Report on the global AIDS epidemic 2012. Geneva: Joint United Nations Programme on HIV/AIDS.
2. Johnson LF, Hallett TB, Rehle TM, Dorrington RE, (2012) The effect of changes in condom usage and antiretroviral treatment coverage on human immunodeficiency virus incidence in South Africa: a model-based analysis. J R Soc Interface 9: 1544-1554.
3. Rehle TM, Hallett TB, Shisana O, Pillay-van Wyk V, Zuma K, et al. (2010) A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008. PLoS ONE 5: e11094 doi:10.1371/journal.pone.0011094.
4. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505.
5. Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell ML, (2013) High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 339: 966-971.
6. Dabis F, Newell ML, Hirschel B, (2010) HIV drugs for treatment, and for prevention. Lancet 375: 2056-2057.
7. Baggaley RF, Ferguson NM, Garnett GP, (2005) The epidemiological impact of antiretroviral use predicted by mathematical models: a review. Emerg Themes Epidemiol 2: 9.
8. Baggaley RF, Garnett GP, Ferguson NM, (2006) Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 3: e124 doi:10.1371/journal.pmed.0030124.
9. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG, (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373: 48-57.
10. Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, et al. (2006) The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 368: 531-536.
11. Salomon JA, Hogan DR, Stover J, Stanecki KA, Walker N, et al. (2005) Integrating HIV prevention and treatment: from slogans to impact. PLoS Med 2: e16 doi:10.1371/journal.pmed.0020016.
12. Stover J, Walker N, Garnett GP, Salomon JA, Stanecki KA, et al. (2002) Can we reverse the HIV/AIDS pandemic with an expanded response? Lancet 360: 73-77.
13. Velasco-Hernandez JX, Gershengorn HB, Blower SM, (2002) Could widespread use of combination antiretroviral therapy eradicate HIV epidemics? Lancet Infect Dis 2: 487-493.
14. Bendavid E, Brandeau ML, Wood R, Owens DK, (2010) Comparative effectiveness of HIV testing and treatment in highly endemic regions. Arch Intern Med 170: 1347-1354.
15. Dodd PJ, Garnett GP, Hallett TB, (2010) Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS 24: 729-735.
16. Kretzschmar ME, van der Loeff MF, Coutinho RA, (2012) Elimination of HIV by test and treat: a phantom of wishful thinking? AIDS 26: 247-248.
17. Powers KA, Ghani AC, Miller WC, Hoffman IF, Pettifor AE, et al. (2011) The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet 378: 256-268.
18. Wagner BG, Kahn JS, Blower S, (2010) Should we try to eliminate HIV epidemics by using a 'test and treat' strategy? AIDS 24: 775-776.
19. Walensky RP, Paltiel AD, Losina E, Morris BL, Scott CA, et al. (2010) Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis 51: 392-400.
20. Eaton JW, Johnson LF, Salomon JA, Bärnighausen T, Bendavid E, et al. (2012) HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 9: e1001245 doi:10.1371/journal.pmed.1001245.
21. Anglemyer A, Rutherford GW, Baggaley RC, Egger M, Siegfried N, (2011) Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev 2011: CD009153.
22. Attia S, Egger M, Muller M, Zwahlen M, Low N, (2009) Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 23: 1397-1404.
23. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, et al. (2010) Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375: 2092-2098.
24. World Health Organization (2009) Rapid advice: antiretroviral therapy for HIV infected in adults and adolescents. Geneva: World Health Organization.
25. Hontelez JA, de Vlas SJ, Tanser F, Bakker R, Bärnighausen T, et al. (2011) The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa. PLoS ONE 6: e21919 doi:10.1371/journal.pone.0021919.
26. Montaner JS, Lima VD, Barrios R, Yip B, Wood E, et al. (2010) Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 376: 532-539.
27. van der Ploeg CPB, Van Vliet C, De Vlas SJ, Ndinya-Achola JO, Fransen L, et al. (1998) STDSIM: a microsimulation model for decision support in STD control. Interfaces 28: 84-100.
28. Korenromp EL, Bakker R, De Vlas SJ, Robinson NJ, Hayes R, et al. (2002) Can behavior change explain increases in the proportion of genital ulcers attributable to herpes in sub-Saharan Africa? A simulation modeling study. Sex Transm Dis 29: 228-238.
29. Korenromp EL, Bakker R, Gray R, Wawer MJ, Serwadda D, et al. (2002) The effect of HIV, behavioural change, and STD syndromic management on STD epidemiology in sub-Saharan Africa: simulations of Uganda. Sex Transm Infect 78 (Suppl 1) (): i55-i63.
30. Korenromp EL, Van Vliet C, Bakker R, De Vlas SJ, Habbema JD, (2000) HIV spread and partnership reduction for different patterns of sexual behavior-a study with the microsimulation model STDSIM. Math Pop Studies 8: 135-173.
31. van Vliet C, Meester EI, Korenromp EL, Singer B, Bakker R, et al. (2001) Focusing strategies of condom use against HIV in different behavioural settings: an evaluation based on a simulation model. Bull World Health Organ 79: 442-454.
32. Korenromp EL, Van Vliet C, Grosskurth H, Gavyole A, Van der Ploeg CP, et al. (2000) Model-based evaluation of single-round mass treatment of sexually transmitted diseases for HIV control in a rural African population. AIDS 14: 573-593.
33. White RG, Freeman EE, Orroth KK, Bakker R, Weiss HA, et al. (2008) Population-level effect of HSV-2 therapy on the incidence of HIV in sub-Saharan Africa. Sex Transm Infect 84 (Suppl 2) (): ii12-ii18.
34. White RG, Glynn JR, Orroth KK, Freeman EE, Bakker R, et al. (2008) Male circumcision for HIV prevention in sub-Saharan Africa: who, what and when? AIDS 22: 1841-1850.
35. Orroth KK, Freeman EE, Bakker R, Buve A, Glynn JR, et al. (2007) Understanding the differences between contrasting HIV epidemics in east and west Africa: results from a simulation model of the Four Cities Study. Sex Transm Infect 83 (Suppl 1) (): i5-i16.
36. Hontelez JA, Lurie MN, Newell ML, Bakker R, Tanser F, et al. (2011) Ageing with HIV in South Africa. AIDS 25: 1665-1667.
37. Hontelez JA, Nagelkerke N, Bärnighausen T, Bakker R, Tanser F, et al. (2011) The potential impact of RV144-like vaccines in rural South Africa: a study using the STDSIM microsimulation model. Vaccine 29: 6100-6106.
38. Hontelez JAC, De Vlas SJ, Baltussen R, Newell M, Bakker R, et al. (2012) The impact of antiretroviral treatment on the age composition of the HIV epidemic in sub-Saharan Africa. AIDS 26 (Suppl 1) (): S19-S30.
39. United Nations Population Division Fertility and Family Planning Section (2008) World fertility data 2008 [database]. New York: United Nations Population Division Fertility and Family Planning Section.
40. World Health Organization (2011) Life tables for WHO member States. Geneva: World Health Organization.
41. World Health Organization (2008) The global burden of disease: 2004 update. Geneva: World Health Organization.
42. Jaffar S, Grant AD, Whitworth J, Smith PG, Whittle H, (2004) The natural history of HIV-1 and HIV-2 infections in adults in Africa: a literature review. Bull World Health Organ 82: 462-469.
43. Morgan D, Mahe C, Mayanja B, Okongo JM, Lubega R, et al. (2002) HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? AIDS 16: 597-603.
44. Boily MC, Baggaley RF, Wang L, Masse B, White RG, et al. (2009) Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 9: 118-129.
45. Hollingsworth TD, Anderson RM, Fraser C, (2008) HIV-1 transmission, by stage of infection. J Infect Dis 198: 687-693.
46. South Africa Department of Health (2003) Demographic and Health Survey of South Africa. Pretoria: South Africa Department of Health.
47. Williams BG, Lloyd-Smith JO, Gouws E, Hankins C, Getz WM, et al. (2006) The potential impact of male circumcision on HIV in sub-Saharan Africa. PLoS Med 3: e262 doi:10.1371/journal.pmed.0030262.
48. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, et al. (2005) Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2: e298 doi:10.1371/journal.pmed.0020298.
49. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, et al. (2007) Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369: 643-656.
50. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, et al. (2007) Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369: 657-666.
51. Mutevedzi PC, Lessells RJ, Rodger AJ, Newell ML, (2011) Association of age with mortality and virological and immunological response to antiretroviral therapy in rural South African adults. PLoS ONE 6: e21795 doi:10.1371/journal.pone.0021795.
52. Williams BG, Korenromp EL, Gouws E, Schmid GP, Auvert B, et al. (2006) HIV infection, antiretroviral therapy, and CD4+ cell count distributions in African populations. J Infect Dis 194: 1450-1458.
53. World Health Organization (2010) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010. Geneva: World Health Organization.
54. Hargreaves JR, Bonell CP, Morison LA, Kim JC, Phetla G, et al. (2007) Explaining continued high HIV prevalence in South Africa: socioeconomic factors, HIV incidence and sexual behaviour change among a rural cohort, 2001-2004. AIDS 21 (Suppl 7) (): S39-S48.
55. Badri M, Maartens G, Mandalia S, Bekker LG, Penrod JR, et al. (2006) Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med 3: e4 doi:10.1371/journal.pmed.0030004.
56. Harling G, Wood R, (2007) The evolving cost of HIV in South Africa: changes in health care cost with duration on antiretroviral therapy for public sector patients. J Acquir Immune Defic Syndr 45: 348-354.
57. World Health Organization (2003) Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization.
58. Cohen MS, Shaw GM, McMichael AJ, Haynes BF, (2011) Acute HIV-1 infection. N Engl J Med 364: 1943-1954.
59. Tanser F, Hosegood V, Bärnighausen T, Herbst K, Nyirenda M, et al. (2008) Cohort profile: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. Int J Epidemiol 37: 956-962.
60. Herbst AJ, Cooke GS, Bärnighausen T, KanyKany A, Tanser F, et al. (2009) Adult mortality and antiretroviral treatment roll-out in rural KwaZulu-Natal, South Africa. Bull World Health Organ 87: 754-762.
61. Hontelez JA, Newell ML, Bland RM, Munnelly K, Lessells RJ, et al. (2012) Human resources needs for universal access to antiretroviral therapy in South Africa: a time and motion study. Hum Resour Health 10: 39.
62. Bärnighausen T, (2010) The role of the health system in HIV treatment-as-prevention. AIDS 24: 2741-2742.
63. Bärnighausen T, Tanser F, Dabis F, Newell ML, (2012) Interventions to improve the performance of HIV health systems for treatment-as-prevention in sub-Saharan Africa: the experimental evidence. Curr Opin HIV AIDS 7: 140-150.
64. Kranzer K, Lewis JJ, Ford N, Zeinecker J, Orrell C, et al. (2010) Treatment interruption in a primary care antiretroviral therapy program in South Africa: cohort analysis of trends and risk factors. J Acquir Immune Defic Syndr 55: e17-e23.
65. Cornell M, Grimsrud A, Fairall L, Fox MP, van Cutsem G, et al. (2010) Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS 24: 2263-2270.
66. Garcia-Calleja JM, Gouws E, Ghys PD, (2006) National population based HIV prevalence surveys in sub-Saharan Africa: results and implications for HIV and AIDS estimates. Sex Transm Infect 82 (Suppl 3) (): iii64-iii70.
67. Nyirenda M, Zaba B, Bärnighausen T, Hosegood V, Newell ML, (2010) Adjusting HIV prevalence for survey non-response using mortality rates: an application of the method using surveillance data from rural South Africa. PLoS ONE 5: e12370 doi:10.1371/journal.pone.0012370.
68. Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, et al. (2012) Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS ONE 7: e30216 doi:10.1371/journal.pone.0030216.
69. Nagelkerke NJ, Jha P, de Vlas SJ, Korenromp EL, Moses S, et al. (2002) Modelling HIV/AIDS epidemics in Botswana and India: impact of interventions to prevent transmission. Bull World Health Organ 80: 89-96.
70. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, et al. (2011) HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 11: 750-759.
71. Manasa J, Katzenstein D, Cassol S, Newell ML, de Oliveira T, (2012) Primary drug resistance in South Africa-data from 10 years of surveys. AIDS Res Hum Retroviruses 28: 558-565.
72. Nachega JB, Mills EJ, Schechter M, (2010) Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. Curr Opin HIV AIDS 5: 70-77.
73. Mills EJ, Bakanda C, Birungi J, Mwesigwa R, Chan K, et al. (2011) Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. AIDS 25: 851-855.
74. Bor J, Herbst AJ, Newell ML, Bärnighausen T, (2013) Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 339: 961-965.
75. Bor J, Tanser F, Newell ML, Bärnighausen T, (2012) In a study of a population cohort in South Africa, HIV patients on antiretrovirals had nearly full recovery of employment. Health Aff (Millwood) 31: 1459-1469.
76. Abdool Karim SS, Churchyard GJ, Karim QA, Lawn SD, (2009) HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet 374: 921-933.
77. United Nations Population Division (2010) World population prospects: the 2010 revision. New York: United Nations Population Division.
78. Shisana O, Rehle T, Simbayi L, Parker W, Zuma K, et al. (2005) South African national HIV prevalence, behavioural risks and communication survey, 2005. Cape Town: HSRC Press.
79. Johnson LF, Alkema L, Dorrington RE, (2010) A Bayesian approach to uncertainty analysis of sexually transmitted infection models. Sex Transm Infect 86: 169-174.
80. Houlihan CF, Bland R, Mutevedzi P, Lessells RJ, Ndirangu J, et al. (2011) Cohort profile: Hlabisa HIV treatment and care programme. Int J Epidemiol 40: 318-326.
81. Williams BG, Granich R, Dye C, (2011) Role of acute infection in HIV transmission. Lancet 378: 1913.
82. Bärnighausen T, Tanser F, Newell ML, (2009) Lack of a decline in HIV incidence in a rural community with high HIV prevalence in South Africa, 2003-2007. AIDS Res Hum Retroviruses 25: 405-409.
83. Kumaranayake L, (2008) The economics of scaling up: cost estimation for HIV/AIDS interventions. AIDS 22 (Suppl 1) (): S23-S33.
84. Johnson LF, Dorrington RE, Bradshaw D, Pallay-Van Wyk V, Rehle T, (2009) Sexual behaviour patterns in South Africa and their association with the spread of HIV: insights from a mathematical model. Demogr Res 21: 289-340.
85. Carael M, Cleland J, Adeokun L, (1991) Overview and selected findings of sexual behaviour surveys. AIDS 5 (Suppl 1) (): S65-S74.
86. Nnko S, Boerma JT, Urassa M, Mwaluko G, Zaba B, (2004) Secretive females or swaggering males? An assessment of the quality of sexual partnership reporting in rural Tanzania. Soc Sci Med 59: 299-310.
87. Weinhardt LS, Forsyth AD, Carey MP, Jaworski BC, Durant LE, (1998) Reliability and validity of self-report measures of HIV-related sexual behavior: progress since 1990 and recommendations for research and practice. Arch Sex Behav 27: 155-180.